Mariana Trovao da Silva

Ms. Mariana Trovao da Silva

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AJAlexandre Soares Ferreira Junior
Alexandre Soares Ferreira Junior
BSBianca Fernanda Rodrigues da Silva
Bianca Fernanda Rodrigues da Silva
JSJefferson Luiz Da Silva
Jefferson Luiz Da Silva
Mariana Trovao da SilvaMariana Trovao da Silva
Mariana Trovao da Silva
JFJoao Victor Piccolo Feliciano
Joao Victor Piccolo Feliciano
Gislane Lelis Vilela de OliveiraGislane Lelis Vilela de Oliveira
Gislane Lelis Vilela de Oliveira
Intestinal dysbiosis represents a critical determinant of clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Distinct microbiota patterns represent potential prognostic biomarkers and therapeutic targets. However, the exponential growth in microbiota research and analytical complexity has created significant interpretive challenges for clinicians. This review provides a synthesis of current literature examining microbiota fingerprints and their clinical implications. We analyzed key studies evaluating the clinical implications of intestinal microbiota fingerprints in allo-HSCT. Additionally, we examined current therapeutic strategies for microbiota modulation and approaches for translating research findings into clinical practice. We identified three major microbiota fingerprints: (1) decreased intestinal microbiota diversity, (2) reduced abundance of short-chain fatty acid-producing bacteria, and (3) Enterococcus domination. These fingerprints are associated with critical clinical outcomes including overall survival, Graft-versus-host disease, transplant-related mortality, and infection-related complications. While fecal microbiota transplantation and dietary interventions appear promising, current studies suffer from limited sample sizes and lack standardized protocols. Despite significant advances in microbiota research, biological, methodological, and logistical challenges continue to hinder its clinical translation. Understanding microbiota fingerprints represents a promising avenue for improving allo-HSCT outcomes. However, successful clinical implementation requires standardized methodologies, mechanistic studies, and multi-center collaborations to translate research into actionable clinical tools.

28 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AJAlexandre Soares Ferreira Junior
Alexandre Soares Ferreira Junior
BSBianca Fernanda Rodrigues da Silva
Bianca Fernanda Rodrigues da Silva
JSJefferson Luiz Da Silva
Jefferson Luiz Da Silva
Mariana Trovao da SilvaMariana Trovao da Silva
Mariana Trovao da Silva
JFJoao Victor Piccolo Feliciano
Joao Victor Piccolo Feliciano
Gislane Lelis Vilela de OliveiraGislane Lelis Vilela de Oliveira
Gislane Lelis Vilela de Oliveira
Intestinal microbiota dysbiosis represents a critical determinant of clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with distinct microbiota patterns serving as potential prognostic biomarkers and therapeutic targets. However, the exponential growth in microbiota research and analytical complexity have created significant interpretive challenges for clinicians. This review provides a synthesis of current literature examining microbiota fingerprints and their clinical implications. We analyzed key studies evaluating the clinical implications of intestinal microbiota fingerprints in allo-HSCT. Additionally, we examined current therapeutic strategies for microbiota modulation and approaches for translating research findings into clinical practice. We identified three major microbiota fingerprints: 1) decreased intestinal diversity, 2) reduced abundance of short-chain fatty acid-producing bacteria, and 3) Enterococcus domination. These fingerprints are associated with critical clinical outcomes including overall survival, graft-versus-host disease, transplant-related mortality, and infectious complications. While fecal microbiota transplantation and dietary interventions appear promising, current studies suffer from limited sample sizes and lack standardized protocols. Despite advances in microbiota research, biological, methodological, and logistical challenges continue to impede clinical translation. Understanding microbiota fingerprints represents a promising avenue for improving allo-HSCT outcomes. However, successful clinical implementation requires standardized methodologies, mechanistic studies, and multi-center collaborations to translate research into actionable clinical tools.